11/26
03:17 pm
cort
Corcept Therapeutics Incorporated (CORT) Modifies Revenue Guidance while Banking on Cushing Syndrome Treatment for Growth [Yahoo! Finance]
Low
Report
Corcept Therapeutics Incorporated (CORT) Modifies Revenue Guidance while Banking on Cushing Syndrome Treatment for Growth [Yahoo! Finance]
11/25
08:07 am
cort
Corcept Therapeutics (NASDAQ:CORT) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $145.00 price target on the stock.
Medium
Report
Corcept Therapeutics (NASDAQ:CORT) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $145.00 price target on the stock.
11/20
01:34 pm
cort
Corcept Therapeutics (NASDAQ:CORT) had its "hold (c-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Corcept Therapeutics (NASDAQ:CORT) had its "hold (c-)" rating reaffirmed by analysts at
Weiss Ratings.
11/18
09:00 am
cort
Corcept Therapeutics (NASDAQ:CORT) is now covered by analysts at Wolfe Research. They set a "peer perform" rating on the stock.
Low
Report
Corcept Therapeutics (NASDAQ:CORT) is now covered by analysts at Wolfe Research. They set a "peer perform" rating on the stock.
11/13
07:07 pm
cort
Branded Pharmaceuticals Stocks Q3 Recap: Benchmarking Corcept (NASDAQ:CORT) [Yahoo! Finance]
Low
Report
Branded Pharmaceuticals Stocks Q3 Recap: Benchmarking Corcept (NASDAQ:CORT) [Yahoo! Finance]
11/5
12:39 am
cort
Corcept Therapeutics Inc (CORT) Q3 2025 Earnings Call Highlights: Revenue Growth Amidst Net ... [Yahoo! Finance]
High
Report
Corcept Therapeutics Inc (CORT) Q3 2025 Earnings Call Highlights: Revenue Growth Amidst Net ... [Yahoo! Finance]
11/4
06:10 pm
cort
Corcept (NASDAQ:CORT) Reports Sales Below Analyst Estimates In Q3 Earnings [Yahoo! Finance]
High
Report
Corcept (NASDAQ:CORT) Reports Sales Below Analyst Estimates In Q3 Earnings [Yahoo! Finance]
11/4
04:05 pm
cort
Corcept Therapeutics Announces Third Quarter Financial Results, Oncology Development Programs and Provides Corporate Update
High
Report
Corcept Therapeutics Announces Third Quarter Financial Results, Oncology Development Programs and Provides Corporate Update
10/28
04:05 pm
cort
Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
Low
Report
Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
10/20
11:28 am
cort
Corcept Therapeutics (NASDAQ:CORT) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $145.00 price target on the stock.
Low
Report
Corcept Therapeutics (NASDAQ:CORT) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $145.00 price target on the stock.
10/19
05:23 am
cort
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment [Yahoo! Finance]
Low
Report
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment [Yahoo! Finance]
10/19
05:15 am
cort
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment
Low
Report
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment
10/17
10:06 pm
cort
H.C. Wainwright Remains Bullish on Corcept Therapeutics Incorporated (CORT) [Yahoo! Finance]
Low
Report
H.C. Wainwright Remains Bullish on Corcept Therapeutics Incorporated (CORT) [Yahoo! Finance]
10/16
08:09 pm
cort
Analyzing Corcept Stock After 53% Surge and Positive FDA Update in 2025 [Yahoo! Finance]
Low
Report
Analyzing Corcept Stock After 53% Surge and Positive FDA Update in 2025 [Yahoo! Finance]
10/14
08:00 am
cort
Corcept Submits Marketing Authorization Application to European Medicines Agency for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer
Low
Report
Corcept Submits Marketing Authorization Application to European Medicines Agency for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer
10/12
06:26 pm
cort
Corcept Therapeutics (CORT) Is Down 16.1% After Distribution Shift and Insider Selling—What's Changed [Yahoo! Finance]
Medium
Report
Corcept Therapeutics (CORT) Is Down 16.1% After Distribution Shift and Insider Selling—What's Changed [Yahoo! Finance]
10/10
08:06 am
cort
Corcept Therapeutics (NASDAQ:CORT) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $145.00 price target on the stock.
High
Report
Corcept Therapeutics (NASDAQ:CORT) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $145.00 price target on the stock.
10/9
05:44 pm
cort
Platinum-Resistant Ovarian Cancer Treatment Market Sees Momentum with Next-Generation Targeted Strategies | DelveInsight [Yahoo! Finance]
High
Report
Platinum-Resistant Ovarian Cancer Treatment Market Sees Momentum with Next-Generation Targeted Strategies | DelveInsight [Yahoo! Finance]
10/4
09:50 am
cort
Corcept Therapeutics (CORT): Evaluating Valuation After New Curant Health Partnership and Pipeline Progress [Yahoo! Finance]
Low
Report
Corcept Therapeutics (CORT): Evaluating Valuation After New Curant Health Partnership and Pipeline Progress [Yahoo! Finance]
10/3
08:47 am
cort
Here's What Makes Corcept Therapeutics (CORT) an Attractive Investment? [Yahoo! Finance]
Low
Report
Here's What Makes Corcept Therapeutics (CORT) an Attractive Investment? [Yahoo! Finance]
10/3
06:38 am
cort
Corcept Therapeutics (NASDAQ:CORT) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
Low
Report
Corcept Therapeutics (NASDAQ:CORT) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
10/1
05:35 am
cort
Corcept Therapeutics Beats Q2 Estimates, Cuts Guidance and Advances NDA for New Cancer Drug [Yahoo! Finance]
Low
Report
Corcept Therapeutics Beats Q2 Estimates, Cuts Guidance and Advances NDA for New Cancer Drug [Yahoo! Finance]
9/29
01:05 am
cort
Corcept Therapeutics Incorporated's (NASDAQ:CORT) large institutional owners must be happy as stock continues to impress, up 4.2% over the past week [Yahoo! Finance]
Low
Report
Corcept Therapeutics Incorporated's (NASDAQ:CORT) large institutional owners must be happy as stock continues to impress, up 4.2% over the past week [Yahoo! Finance]
9/26
12:08 pm
cort
Corcept Primed For An Upside EPS Surprise [Seeking Alpha]
Low
Report
Corcept Primed For An Upside EPS Surprise [Seeking Alpha]
9/25
08:43 am
cort
Corcept Therapeutics (NASDAQ:CORT) had its "buy" rating reaffirmed by analysts at Canaccord Genuity Group Inc.. They now have a $140.00 price target on the stock.
Low
Report
Corcept Therapeutics (NASDAQ:CORT) had its "buy" rating reaffirmed by analysts at Canaccord Genuity Group Inc.. They now have a $140.00 price target on the stock.